Lung cancer treatment cost in Thailand

Lung cancer treatment cost in Thailand by stage, mutation, and respiratory risk

The cost of lung cancer care can change after a biopsy, staging scan, molecular panel, or multidisciplinary review. A useful plan separates tissue acquisition, PET-CT or other staging, bronchoscopy, surgery, radiation, chemotherapy, targeted tablets, immunotherapy, oxygen, and follow-up. Thailand offers tertiary thoracic and oncology services, but the named hospital must show how it manages airway, bleeding, infection, respiratory failure, and urgent admission during an international patient’s stay.

How much does lung cancer treatment cost in Thailand?

A diagnostic and surgery-led pathway for selected early lung cancer may be planned at THB 495,000 to 1,320,000, approximately USD 15,000 to 40,000. Chemoradiation or a multi-phase early and locally advanced plan may range from THB 990,000 to 2,475,000, around USD 30,000 to 75,000. Advanced disease requiring mutation-directed tablets, immunotherapy, repeated scans, oxygen, or complication care may reach THB 1,650,000 to 5,940,000+, approximately USD 50,000 to 180,000+. These are planning bands rather than a promise or hospital quote.

USD examples use approximately THB 33 per USD, based on the Bank of Thailand exchange-rate context checked in July 2026. Drug quotations may be issued in THB or USD and can change with weight, dose, brand, supply, and exchange rate. Confirm which currency controls the invoice and whether the estimate includes pharmacy administration.

Review cost scenarios Upload reports

Let Us Help You

Share the basics and the Virello team will guide you toward the next step.

Prefer email? Write to support@virellohealth.com.

Patient Name

Country

Phone Number

Describe The Current Medical Problem

Reviewed 2026-07-19

Clinical review: Virello Health Clinical Content Team · Editorial review: Virello Health Research Team

Billing context: THB and USD

Biopsy comes before precision treatment

A cytology label alone may not provide enough tissue for histology, driver mutations, and immune-marker testing.

Molecular results alter price

EGFR, ALK, ROS1, BRAF, MET, RET, KRAS, NTRK, and other findings can move care toward targeted medicine rather than a standard chemotherapy plan.

Breathing reserve matters

Spirometry, oxygen need, emphysema, infection, heart function, and prior treatment influence whether surgery or radiation is safe.

A tablet is still a treatment course

Targeted medicine can continue for months and needs scans, blood tests, side-effect management, and a reliable pharmacy supply.

Radiation needs precision

Simulation, motion management, dose planning, image guidance, and lung and heart protection should be described before booking.

Cost at a glance

Planning scenarios for lung cancer treatment in Thailand

The scenarios separate routine and complex pathways. They are not fixed packages and should be replaced by a report-led hospital estimate before travel.

Estimated lung cancer treatment cost scenarios in Thailand
Scenario	THB	USD	Patient and treatment context	Planning scope
Early-stage surgery pathway	THB 495,000 - 1,320,000	USD 15,000 - 40,000	A potentially resectable lesion with adequate lung reserve, complete staging, and no planned prolonged systemic or critical-care course.	Should include thoracic review, biopsy or pathology assumptions, operation, anesthesia, room, chest drain care, routine imaging, and discharge review.
Locally advanced combined care	THB 990,000 - 2,475,000	USD 30,000 - 75,000	A pathway using chemotherapy, radiation, surgery, concurrent chemoradiation, or consolidation medicine over several phases.	Price radiation planning and fractions, each drug, blood tests, admissions, response scans, and the time between phases.
Advanced molecular or immune treatment	THB 1,650,000 - 5,940,000+	USD 50,000 - 180,000+	Metastatic disease with EGFR, ALK, ROS1, other actionable findings, high immune-marker expression, or a prolonged immune and targeted sequence.	Use a named medicine and a response-dependent duration; tablets, infusions, scans, and toxicity admission should not be hidden in one package.

Usually included

Check the clinical package scope

Thoracic and oncology review

Pulmonology, thoracic surgery, medical oncology, radiation oncology, radiology, pathology, and anesthesia input as appropriate.

Ask whether a tumor board reviews the records.

Defined diagnostic work

Only the bronchoscopy, biopsy, pathology, molecular, stage imaging, or repeat test written in the quote.

Tissue quantity and biomarker scope should be explicit.

Quoted treatment phase

Named surgery, radiation course, chemotherapy regimen, targeted drug, or immune treatment with dose and duration assumptions.

A first cycle or first month is not a complete pathway.

Discharge and handover

Drain or wound instructions, oxygen plan, medicines, pathology, scan schedule, emergency contact, and home oncologist communication.

Pulmonary rehabilitation may be separate.

Confirm separately

Charges that may sit outside the range

Tissue and biomarker additions

Repeat bronchoscopy, EBUS, biopsy, liquid biopsy, broad sequencing, PD-L1, outside slide review, or tissue courier.

Confirm test platform and turnaround.

Respiratory and ICU support

Oxygen, high-flow support, ventilation, chest-tube complications, pulmonary embolism, sepsis, or ICU care when separately charged.

High-risk patients need daily rates.

Systemic treatment changes

Extra cycles, targeted tablets, immunotherapy, dose changes, transfusions, growth factors, anti-nausea drugs, or treatment for toxicity.

Request the generic name and pharmacy terms.

Unplanned procedures

Pleural drainage, airway stent, repeat biopsy, thoracic re-operation, radiation replanning, or emergency admission.

A contingency reserve is essential.

Candidate context

Who may be considered and what else may be discussed

Lung cancer treatment is chosen after the team understands the histologic type, stage, resectability, lymph nodes, distant disease, molecular drivers, PD-L1 or other immune markers, performance status, lung and heart reserve, smoking history, infection risk, and the patient’s goals. Early disease may involve surgery or stereotactic radiation. Locally advanced disease can need concurrent treatment. Advanced disease may be controlled with targeted tablets, immunotherapy, chemotherapy, or combinations. The cost plan should follow the evidence and sequence for that individual.

Information that shapes suitability

Enough tissue for a decision

Biopsy must distinguish non-small-cell, small-cell, neuroendocrine, metastatic, or another diagnosis and support the tests that could change treatment.

Complete stage assessment

Chest and upper-abdominal imaging, PET-CT, brain imaging, node sampling, and selected bone or other studies define resectability and intent.

Lung function and fitness

Spirometry, diffusion, oxygen need, emphysema, nutrition, exercise tolerance, heart condition, and frailty affect surgery or radiation tolerance.

Molecular and immune profile

Actionable driver findings and PD-L1 or related markers may change chemotherapy, targeted medicine, immunotherapy, and duration.

Continuity readiness

The patient needs a pharmacy plan, infection warning plan, scan schedule, home oncologist, and access to urgent respiratory care after travel.

Alternatives or sequencing questions

Surgery

Lobectomy, segmentectomy, pneumonectomy, node dissection, or minimally invasive resection may fit selected localized disease and lung reserve.

Stereotactic radiation

Focused radiation can be considered for selected small tumors or patients whose operative risk is high.

Chemoradiation

Concurrent or sequential treatment can be used when disease is locally advanced or surgery is not the first step.

Targeted or immune treatment

Advanced cancer may be managed with mutation-directed medicine, immunotherapy, chemotherapy, or a planned combination based on pathology.

Procedure variations

Why the named procedure does not have one price

Technique, device, medicine, treatment extent, and prior care can change both the clinical plan and the estimate.

Minimally invasive lung resection

Video-assisted or robotic approaches may reduce access trauma for appropriate anatomy and an experienced team.

Conversion, node work, and chest-drain terms remain important.

Open thoracotomy

A larger incision may be necessary for tumor location, vessels, adhesions, or complex resection.

Expect a different pain, mobility, and stay plan.

Stereotactic body radiation

A small number of precise high-dose sessions may be used for selected lesions.

Motion management and lung constraints should be explained.

Concurrent chemoradiation

Chemotherapy and radiation are delivered in a coordinated sequence for selected locally advanced cases.

Blood counts, swallowing, lung inflammation, and treatment breaks need monitoring.

Targeted oral therapy

A driver mutation may support an oral medicine with repeated scans and laboratory review.

Verify registration, stock, dose, duration, and what happens after progression.

City comparison

Cost and capability by city in Thailand

Only cities with evidence for the procedure should appear here. A city range does not prove that every hospital in that city can manage the same case complexity.

Estimated lung cancer treatment costs and planning context by city in Thailand
City	Local range	USD range	Capability context	Stay planning
Bangkok	THB 594,000 - 5,940,000+	USD 18,000 - 180,000+	Broad access to thoracic surgery, molecular pathology, radiation, targeted medicines, immune treatment, and ICU support.	Confirm whether all stages and complications are managed at the same campus.
Chiang Mai	THB 561,000 - 4,950,000+	USD 17,000 - 150,000+	University and private tertiary services may support surgery, radiation, and systemic treatment.	Ask about molecular testing, respiratory ICU, and escalation to Bangkok.
Phuket	THB 594,000 - 4,620,000+	USD 18,000 - 140,000+	International services are accessible, while advanced thoracic and molecular depth must be checked.	Do not confuse an international desk with a complete thoracic oncology program.
Pattaya and Chon Buri	THB 561,000 - 4,290,000+	USD 17,000 - 130,000+	Selected regional hospitals provide oncology and pulmonary care near the eastern corridor.	Verify airway intervention, ICU, radiation, and emergency transfer arrangements.
Khon Kaen	THB 528,000 - 4,125,000+	USD 16,000 - 125,000+	A tertiary northeastern route can suit planned surgery or stable medicine after multidisciplinary review.	Make biomarker turnaround and pharmacy supply part of the quote.
Hat Yai and Songkhla	THB 528,000 - 4,125,000+	USD 16,000 - 125,000+	Southern regional services may manage selected thoracic and systemic pathways.	Ask how acute breathlessness, infection, and drug reactions are handled.
Nakhon Ratchasima	THB 495,000 - 3,960,000+	USD 15,000 - 120,000+	Large regional centers may offer surgery, infusion, and follow-up for appropriate patients.	A named molecular pathology and referral route should be visible.
Chiang Rai	THB 495,000 - 3,795,000+	USD 15,000 - 115,000+	Regional assessment is possible; advanced surgery and targeted treatment depend on the selected hospital.	Confirm how quickly a patient can be moved for complex care.
Udon Thani	THB 495,000 - 3,795,000+	USD 15,000 - 115,000+	Planned infusion and regional follow-up may be feasible when a tertiary consultant is involved.	Check oxygen, infection, and medicine continuity outside Bangkok.
Rayong	THB 528,000 - 4,125,000+	USD 16,000 - 125,000+	Eastern transport links may help selected planned care and follow-up.	Convenience should follow clinical capability, not replace it.

Estimate variables

What can change the final hospital cost

Stage and resectability

Localized, node-positive, locally advanced, recurrent, and metastatic disease need different treatment phases and durations.

Ask the team to state curative or disease-control intent.

Biopsy and molecular scope

Bronchoscopy, EBUS, tissue quantity, sequencing, PD-L1, and repeat review affect initial cost and treatment selection.

Do not skip biomarker work to save on the first invoice.

Respiratory reserve

COPD, oxygen, pulmonary hypertension, infection, prior radiation, and heart disease affect anesthesia, ICU, and recovery.

Bring current pulmonary tests.

Medicine identity

Chemotherapy, targeted tablets, immune drugs, dose, body size, cycle count, and duration create wide price differences.

Per-infusion figures are incomplete without duration.

Radiation technique

Stereotactic, conventional, intensity-modulated, proton availability, motion management, and fractions change resources.

Price simulation through final review.

Medical cost breakdown

Before admission, in hospital, and after discharge

Diagnostics and preparation

Tissue acquisition

Bronchoscopy, EBUS, CT-guided biopsy, pleural sampling, pathology, immunohistochemistry, and molecular testing.

Ask how nondiagnostic samples are handled.

Stage imaging

CT chest and abdomen, PET-CT, brain MRI, node assessment, bone imaging, or other scans selected by the team.

Avoid scans that do not answer a clinical question.

Fitness and treatment safety

Pulmonary function, ECG, echo, blood tests, oxygen assessment, infection screen, nutrition, and performance status.

Some tests require local repeat before anesthesia or drug treatment.

Admission and treatment

Biopsy or procedure stay

Pre-procedure evaluation, sedation or anesthesia, tissue handling, imaging, observation, and pathology communication.

Bleeding and pneumothorax plans should be written.

Thoracic operation

Anesthesia, resection, node dissection, theatre, chest tube, ward, pain service, imaging, and discharge review.

Ask about open conversion and extra nights.

Day-care or radiation

Drug preparation, infusion nursing, laboratory review, radiation planning, fractions, and on-treatment assessment.

Medicine and administration may be separate lines.

Recovery and follow-up

Breathing and chest recovery

Chest-drain management, pain control, spirometry, walking, cough support, wound care, and oxygen review.

New breathlessness requires urgent assessment.

Treatment toxicity

Blood counts, nausea, diarrhea, rash, thyroid or liver effects, pneumonitis, infection, and transfusion support.

Ask for an after-hours contact.

Long-term monitoring

Scans, pulmonary rehabilitation, smoking cessation, targeted-drug review, immune surveillance, and home oncology follow-up.

A return flight is not the end of care.

Complete journey budget

Plan beyond the hospital invoice

Patient and attendant costs should be modeled separately from the medical estimate, with flexible dates and a contingency reserve.

Record preparation

Pathology, imaging, bronchoscopy, pulmonary tests, medicines, oxygen details, visa, insurance, and hospital acceptance.

Source files improve triage.

Treatment stay

Hospital, day-care, accessible housing, companion, oxygen or transport, meals, translation, and added nights.

A radiation or drug course may require repeated attendance.

Return reserve

Fever or breathlessness evaluation, repeat scan, delayed cycle, oxygen, changed flight, home oncologist, and emergency plan.

Keep bookings flexible.

Country access

Rules and practical requirements to verify

Visa, donor, fertility, medicine, licensing, and treatment-access requirements can change. Confirm current rules with the relevant authority and treating hospital.

Confirm the named cancer hospital

Check Thailand Medical Hub and hospital international-department information for the exact campus, service, and contact before deposit.

Check thoracic and radiation capability

Ask for the thoracic surgeon, interventional pulmonologist, radiation oncologist, physicist, ICU, and backup pathway.

Verify molecular medicine access

Confirm the generic drug, indication, Thai availability, registration or access route, dose, supply, and follow-up scans.

Use a tissue chain of custody

Agree pathology release, courier, consent, privacy, translation, slide return, and the receiving laboratory’s acceptance.

Use official visa guidance

Check the Thailand e-Visa portal or relevant embassy and allow for respiratory recovery and delayed discharge.

Hospital selection

Compare capability before package price

Thoracic tumor board

Thoracic surgeon, pulmonologist, medical and radiation oncologists, radiologist, pathologist, anesthetist, and palliative or rehabilitation support.

Ask for the decision sequence in writing.

Airway and biopsy safety

Bronchoscopy, EBUS, pleural procedures, bleeding control, pneumothorax treatment, and respiratory monitoring.

The international desk does not prove procedural depth.

Molecular and pharmacy service

Tissue testing, immune markers, sequencing, targeted medicines, immune drugs, dose monitoring, and emergency toxicity care.

Request a pharmacy stock confirmation.

Radiation and ICU

Planning, motion management, physics review, machine backup, high-dependency care, ventilation, and infection response.

Match resource depth to risk.

Continuity record

Pathology, operation, drug, scan, oxygen, discharge, warning signs, and home-oncologist handover are supplied.

Obtain records before leaving Thailand.

Treating team

Specialists and support that may matter

Thoracic surgeon

Assesses resectability, lung reserve, node strategy, minimally invasive or open approach, chest drain, and postoperative risk.

Pulmonologist or interventional bronchoscopist

Plans biopsy, airway work, pleural procedures, oxygen assessment, and management of breathing complications.

Medical oncologist

Interprets histology, driver mutations, immune markers, chemotherapy, targeted tablets, immunotherapy, and progression.

Radiation oncologist and physicist

Designs curative, stereotactic, palliative, or combined radiation while protecting lung, heart, esophagus, and spinal cord.

Respiratory rehabilitation team

Supports breathing exercises, mobility, nutrition, smoking cessation, symptom monitoring, and safe return travel.

Treatment timeline

From report review to return-home follow-up

Remote thoracic review

Send pathology, bronchoscopy, CT or PET images, brain scan, pulmonary tests, oxygen history, medicines, and symptoms.

Diagnostic completion

The Thai team confirms histology, stage, resectability, molecular tests, immune markers, and fitness before selecting treatment.

Treatment decision

Surgery, radiation, chemoradiation, chemotherapy, targeted therapy, immunotherapy, or supportive care is sequenced with intent.

Active treatment

The patient receives the named operation, fractions, infusions, tablets, or combination with blood, scan, and symptom monitoring.

Early recovery or toxicity review

Chest tubes, oxygen, wound, fever, pneumonitis, blood counts, nutrition, and mobility determine readiness for hotel or flight.

Home continuity

The home team receives pathology, molecular findings, treatment dates, next scan, medicine supply, red flags, and contact instructions.

Risks and edge cases

Events that can change the plan, stay, or cost

Nondiagnostic biopsy

A small or necrotic sample may not establish subtype or biomarkers, requiring another procedure and extra time.

Ask about tissue adequacy before travel.

Pneumothorax or bleeding

Biopsy can require observation, chest drainage, admission, or delayed flight.

The hospital should state emergency rates.

Postoperative air leak

Persistent air leak, infection, fluid, arrhythmia, or weak breathing can extend the ward stay.

Do not schedule a fixed return date.

Immune pneumonitis

Cough, fever, falling oxygen, or breathlessness during immune treatment can be urgent and may require steroids or admission.

Do not self-treat respiratory symptoms.

Drug resistance

Targeted treatment can stop working; a new biopsy, liquid biopsy, medicine, or radiation plan may follow.

Budget by response, not a guaranteed duration.

Home oxygen and flight

Oxygen need, recent chest procedure, infection, or low reserve can make air travel unsafe or require airline approval.

Fit-to-fly is a clinical decision.

Destination comparison

Compare India, Turkey, and Thailand for this procedure

The most suitable destination depends on the individual case, required team, treatment availability, travel route, legal eligibility, budget, and continuity after returning home.

Procedure planning comparison across India, Turkey, and Thailand
Decision factor	India	Turkey	Thailand	How to use this
Specialist model	Large thoracic and oncology network with strong city variation and many value-oriented pathways.	Private and university programs often package international thoracic and oncology care.	Bangkok has broad international oncology depth, while regional centers may suit selected stable treatment.	Compare molecular, thoracic, radiation, ICU, and pharmacy capability.
Cost behavior	Procedure, cycle, radiation, and medicine prices often appear as separate components.	Foreign-currency packages can obscure duration and drug assumptions.	THB estimates may look attractive but must disclose biomarker, ICU, oxygen, and repeat-scan additions.	Request phase-based pricing.
Regional use	Tier 2 cities may support surgery, infusion, or follow-up under a tertiary plan.	Regional care can work after confirming the named hospital and referral route.	Regional hospitals may manage planned care, with complex airway or cellular needs concentrated in major centers.	Select on capability and continuity.
Patient geography	Convenient for South Asian, Gulf, and African routes.	Convenient for Europe, Gulf, and Central Asia.	Convenient for Southeast Asia and selected Asian routes.	Consider flights, companion, oxygen, and home follow-up.

Decision guidance

When Thailand may fit and when to keep comparing

Thailand may fit when

Biopsy and images are accepted by a named thoracic team, molecular testing is available, the treatment sequence is clear, and respiratory emergency care is documented.

Keep comparing when

The proposal skips molecular testing, sells a surgery-only package, hides drug duration, or cannot explain oxygen, ICU, pneumothorax, and infection care.

A regional city may fit when

The center has a tertiary consultant, pathology and pharmacy link, radiation or surgery plan, emergency admission, and reliable transfer pathway.

Urgent local care comes first when

The patient has severe breathlessness, blue lips, confusion, coughing blood, shock, or rapidly worsening oxygen levels.

Reports for review

Prepare a case file before requesting estimates

Send biopsy and pathology, bronchoscopy or EBUS notes, CT and PET-CT source images, brain imaging, molecular and immune results, pulmonary function, oxygen history, blood tests, medicines, smoking history, prior cancer care, allergies, and the symptom timeline. Ask for a written Thai plan naming histology, stage, intent, treatment, drug and radiation assumptions, hospital days, respiratory contingencies, THB validity, and home handover.

Upload medical reports

Cancer evidence

Tissue report

Include histology, grade, immunohistochemistry, molecular drivers, PD-L1 or other immune marker, and sample adequacy.

Imaging

Provide CT, PET-CT, MRI brain, node studies, chest radiographs, and source images with dates.

Pulmonary history

Add spirometry, diffusion, oxygen readings, COPD or asthma treatment, infection history, and exercise tolerance.

Previous treatment

List surgery, radiation, chemotherapy, targeted, immune, steroid, drainage, or admission with response and toxicity.

Safety and travel evidence

Medical conditions

Include heart, kidney, liver, clotting, diabetes, infection, nutrition, and smoking information.

Medicines

List inhalers, oxygen, anticoagulants, steroids, cancer medicines, supplements, and allergies.

Travel file

Share passport, visa, companion, language, accommodation, insurance, mobility, and flight flexibility.

Home team

Name the oncologist, pulmonologist, emergency hospital, oxygen provider, and rehabilitation service.

Quote questions

Tissue scope

Ask what biopsy, pathology, molecular, immune, and repeat-test work is included.

Respiratory scope

Request chest tube, oxygen, ICU, ventilation, infection, embolism, and emergency-admission terms.

Drug scope

Confirm generic name, brand, dose, cycle or tablet duration, pharmacy stock, monitoring, and progression plan.

Return plan

Agree scan timing, fit-to-fly conditions, records, changed flights, and home oncologist communication.

Common questions

Questions about cost, travel, and follow-up

What is lung cancer treatment cost in Thailand?

A selected early-stage surgery pathway may be THB 495,000 to 1,320,000, while combined or advanced treatment can range from THB 990,000 to 5,940,000 or more.

Why is molecular testing important?

Driver mutations and immune markers can change the treatment from standard chemotherapy to a targeted tablet or immunotherapy, altering both cost and duration.

Does surgery include chemotherapy?

Usually not unless the hospital names the regimen, number of cycles, drug, administration, blood tests, and response scans.

Can a regional Thai hospital treat lung cancer?

Selected regional programs can manage planned surgery, radiation, or stable infusions, but confirm pathology, molecular access, respiratory ICU, and referral support.

How much does immunotherapy add?

The agent, dose, infusion interval, biomarker, number of months, and immune-toxicity monitoring determine the added amount; a single infusion is not the full cost.

Can I fly after a lung biopsy?

Not automatically. Pneumothorax, chest tube, bleeding, oxygen need, and the treating team’s fit-to-fly assessment determine timing.

How long does lung cancer treatment take?

Surgery may be one admission, radiation can take several visits or weeks, and systemic treatment often continues across multiple cycles or months.

What if the biopsy is too small?

A repeat biopsy or another tissue test may be needed to confirm subtype and biomarkers; this can change cost and travel time.

Are targeted tablets included in a hospital package?

Only if the quote identifies the medicine, dose, supply, monitoring, price validity, and what happens if the disease progresses.

What records should I send?

Send pathology, CT or PET images, bronchoscopy, brain scan, molecular results, pulmonary tests, oxygen history, medicines, and prior treatment.

Review and sources

How this guide was prepared

These bands distinguish surgery-led early disease, combined local and systemic treatment, and advanced molecular or immune care. The working conversion is approximately THB 33 per USD using the Bank of Thailand source checked in July 2026. The estimate includes the less visible cost drivers: biopsy adequacy, molecular testing, stage imaging, lung function, oxygen, radiation, drug duration, ICU, housing, and home continuity. National Cancer Institute, Thailand Medical Hub, accreditation, and hospital sources inform the research frame; the treating team must issue the final estimate.

This page is educational and cannot diagnose, stage, or treat lung cancer, guarantee medicine access, or certify a hospital’s current authorization. A thoracic and oncology team should review source pathology and imaging. Severe breathlessness, coughing blood, blue lips, confusion, shock, or rapidly falling oxygen requires urgent local medical attention.

Related planning